AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$CRNX

Okey Stephanie sold (to issuer) $1.0M of CRNX

Okey Stephanie sold (to issuer) 12,325 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.05M total) across 2 trades on 2026-09-01.

Original reporting
SEC EDGAR · Okey Stephanie
Published Sep 1, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRNX
Neutral
medium confidence
Mentioned
$CRNX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRNXNeutralLow
01

Why it matters

The complete divestiture may be viewed as a slight bearish cue, but the transaction size is modest.

02

Market read

Routine insider sale with limited immediate market impact.

03

What to watch

Director may have tax or personal reasons unrelated to company outlook.

Relevance 6/10Novelty 4/10Timing: reported on 2026-09-01 (same day filing)

Background

Form 4 filings disclose insider transactions; this one shows a director exiting the company entirely.

Company-level read

Ticker impact

$CRNXNeutralMedium confidence
Context

Director Okey Stephanie sold all 12,325 shares for $1.05M via a Form 4 filing.

Expected impact

Minor downward pressure in the short term.

Evidence & confidence

Sale size is modest relative to market cap; impact likely limited.

Market effects

Sector

No broader sector impact; typical insider transaction.

Regional

Limited to US biotech sector sentiment.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

Sale could be routine liquidity need, not a negative signal.

Key entities

  • Company
    Crinetics Pharmaceuticals, Inc.

    Biopharma listed on NASDAQ under ticker CRNX.

  • Insider
    Okey Stephanie

    Director of Crinetics who sold all holdings.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRNX insider trading history →

Related articles

SEP 2
$VRTXHighAI 9/10

Vertex Completes $10 Billion Acquisition Of Crinetics Pharmaceuticals

Vertex Pharmaceuticals completed its $10 billion acquisition of Crinetics Pharmaceuticals, adding PALSONIFY and atumelnant to its portfolio. The deal, closed on September 1, 2026, is expected to boost revenue growth and become accretive to non-GAAP operating income by 2029. Vertex also announced leadership changes, including a new CFO.

pulse2.com2 min
SEP 2
$VRTXLowAI 9/10

What Does Crinetics Pharmaceuticals (CRNX) Delisting Mean After The Takeover Closed?

Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (CRNX), delisting it from Nasdaq. Crinetics is now a subsidiary, with leadership changes announced. The $10B deal was funded by cash, debt, and $4.5B in bridge financing. Vertex gains exposure to Crinetics' endocrine disease treatments. Investors should watch for updates on pipeline and commercial priorities.

simplywall.st2 min
SEP 1
$VRTXHighAI 9/10

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

Vertex Pharmaceuticals (VRTX) completed its $10B acquisition of Crinetics Pharmaceuticals (CRNX) on September 1, 2026. The deal adds PALSONIFY and atumelnant to Vertex's pipeline, with potential peak revenue of $5B. Vertex also announced leadership changes, including Jonathan Poole's appointment as EVP, CFO in 2027 and Jasper van Grunsven joining as EVP, Chief Pain and New Product Planning Officer.

investingnews.com2 min
AUG 30
$VRTXHighAI 9/10

Crinetics Acquisition Creates A ‘Fifth Commercial Pillar’ For Vertex, Says Analyst – Why HC Wainwright Sees A 24% Upside Potential In VRTX Stock

Vertex Pharmaceuticals (VRTX) announced a $10 billion acquisition of Crinetics Pharmaceuticals (CRNX) for $85 per share, a 100% premium. Analyst Andrew Fein of H.C. Wainwright called it a strategic fit, adding a fifth commercial pillar. VRTX stock fell 2.5%, while CRNX surged 99%. Fein set a $641 price target for VRTX, a 24% upside. The deal is expected to close in Q3 2026 and contribute $5 billion in annual revenue by 2029.

stocktwits.com2 min